The paper "GlaxoSmithKline - Management" is an outstanding example of a management assignment. GlaxoSmithKline is a global leader in the pharmaceutical industry and its products are consumed worldwide. The company is profitable due to the high sales that it registers annually. However, the company has been faced with legal action due to its unethical practices with regard to some of its drugs. The failure of the company to disclose the harmful side effects of Avandia and Paxil was an indication that the company had serious ethical problems as the side effects of the drugs were quite harmful.
The ethical lapse within the company has also been perpetrated by the leadership in some of the instances which includes sacking an employee for whistleblowing. The competitive environment within the industry as well as the merger contributed to the failure of the company to deal with the ethical issues. This is because the mergers meant that the employees and management were used to different organizational cultures. The leadership of the company was also unable to adequately address the issues of ethics due to lack of oversight.
However, the company can improve its operation and it can also enhance its reputation by coming up with policies that encourage the staff to be ethical. On the other hand, the company may also review its codes of conduct for the purposes of improving ethics. Introduction GlaxoSmithKline is a pharmaceutical company that is well known over the world due to its products. The company collects about $ 25 billion every year from the sale of its pharmaceutical products. The company is also considered a global leader in the industry due to the success that it has experienced.
It is also important to note that the company was a result of a merger of several small pharmaceutical companies. The company has its headquarters based in the United States of America although its products are sold worldwide. It has business divisions that have been distributed in all the continents.
Seibold, J, 2012, Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta‐analysis of 629 subjects with diffuse cutaneous systemic sclerosis, Arthritis & Rheumatism, 64(10), 3420-3429.
Brody, H, 2010, Professional medical organizations and commercial conflicts of interest: ethical issues, The Annals of Family Medicine, 8(4), 354-358.
Ide, N, 2011, The ClinicalTrials. gov results database—update and key issues, New England Journal of Medicine, 364(9), 852-860.
Steen, R, 2011, Retractions in the scientific literature: is the incidence of research fraud increasing?, Journal of Medical Ethics, 37(4), 249-253.
Sismondo, S, 2010, Publication ethics and the ghost management of medical publication, Bioethics, 24(6), 273-283.
Evans, B, 2012, The Ethics of Postmarketing Observational Studies of Drug Safety Under Section 505 (o)(3) of the Food, Drug, and Cosmetic Act, American Journal of Law and Medicine, 38.
Kominski, G, 2011, Changing the US health care system: Key issues in health services policy and management, Wiley. com.
Eichler, H, 2010, Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers, Nature Reviews Drug Discovery, 9(4), 277-291.
Jacqz-Aigrain, E, 2011, Drug policy in Europe: Research and funding in neonates: Current challenges, future perspectives, new opportunities, Early human development, 87, S27-S30.
Carpenter, D, 2010, Reputation and power: organizational image and pharmaceutical regulation at the FDA, Princeton University Press.
Sampat, B, 2011, What are the respective roles of the public and private sectors in pharmaceutical innovation?, Health Affairs, 30(2), 332-339.